Amicus Therapeutics' stock experienced a significant plummet of 7.51% in the pre-market trading session on Wednesday. This downward movement came after the company reported its fourth-quarter earnings results, which fell short of market expectations.
According to the earnings report, Amicus Therapeutics reported earnings per share (EPS) of $0.09, missing the Zacks Consensus Estimate of $0.10 per share. Additionally, the company's quarterly revenue of $149.71 million narrowly missed the consensus estimate of $149.88 million.
The disappointing earnings results raised concerns among investors, leading to the substantial sell-off in the pre-market session. Analysts suggest that the company's performance and future outlook will be closely scrutinized during the upcoming earnings call, which may provide further insights into the stock's price movement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。